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Abstract 20 
INTRODUCTION: Genome-wide association studies (GWASs) in frontotemporal 21 
dementia (FTD) showed limited success in identifying associated loci. This is possibly 22 
due to small sample size, allelic heterogeneity, small effect sizes of single genetic 23 
variants, and the necessity to statistically correct for testing millions of genetic variants.  24 
METHODS: To overcome these issues, we performed gene-based association studies 25 
on 3348 clinically identified FTD cases and 9390 controls (discovery, replication and 26 
joint-cohort analyses). 27 
RESULTS: We report association of APOE and TOMM40 with behavioural FTD 28 
(bvFTD), and ARHGAP35 and SERPINA1 with progressive non-fluent aphasia (PNFA). 29 
Further, we found the ε2 and ε4 alleles of APOE harbouring protective and risk 30 
increasing effects, respectively, in clinical subtypes of FTD. 31 
DISCUSSION: The APOE-locus association with bvFTD indicates its potential risk-32 
increasing role across different neurodegenerative diseases, whilst the novel genetic 33 
association of ARHGAP35 and SERPINA1 with PNFA points towards a potential role of 34 
the stress-signalling pathway in its pathophysiology. 35 
Keywords: 36 
Gene-based association study, GWAS, FTD, MAGMA, bvFTD, APOE, TOMM40, 37 
epsilon alleles, PNFA, stress-signalling pathway, ARHGAP35, GRLF1, SERPINA1, 38 
FTD-MND, C9orf72 39 
  40 
Research in context (< 150 words) 41 
Frontotemporal dementia (FTD) is a clinically heterogeneous disorder, presenting 42 
mainly with behavioural or language symptoms and co-occurring with motor neuron 43 
disease in a minority of cases. Recent single marker genome-wide association studies 44 
(GWAS) on FTD showed limited success in identifying associated loci possibly due to 45 
small sample size, allelic heterogeneity and the stringency of the Bonferroni correction. 46 
In this study, we performed an alternative joint-SNP gene-based analyses using the 47 
GWAS data on 3348 clinically identified FTD cases and 9390 controls. We identified 48 
association of APOE and TOMM40 genes with behavioural FTD, and ARHGAP35 and 49 
SERPINA1 genes with progressive non-fluent aphasia. The APOE gene association with 50 
behavioural FTD points towards its potential role across different neurodegenerative 51 
diseases. This is the first work reporting a significant genetic association with 52 
progressive non-fluent aphasia: SERPINA1 and ARHGAP35 point to a potential role of 53 
a stress-pathway in the pathogenesis of progressive non-fluent aphasia. 54 
  55 
Highlights 56 
• Gene-based association study reports association of APOE and TOMM40 genes 57 
with bvFTD, and ARHGAP35 and SERPINA1 with PNFA. 58 
• ε2 and ε4 alleles of APOE, respectively, show protective and disease increasing 59 
effects for clinical subtypes of FTD. 60 
• The TOMM40 gene harbours genetic variations associated with bvFTD that is 61 
independent of the epsilon alleles. 62 
• The ARHGAP35 and SERPINA1 gene associations with PNFA guides towards 63 
the role of stress-signalling pathway in its pathophysiology. 64 
  65 
Abbreveations: 66 
bvFTD = Behavioural variant of frontotemporal dementia 67 
CBG = Corticosteroid binding globulin 68 
GWAS = Genome-wide association study 69 
IFGC = International FTD-GWAS consortium 70 
FTD = Frontotemporal dementia 71 
FTD-MND = Frontotemporal dementia with motor neuron disease 72 
FTLD = Frontotemporal lobar degeneration 73 
hGR = Human glucocorticoid receptor 74 
LD = Linkage disequilibrium 75 
MAGMA = Multi-marker Analysis of GenoMic Annotation 76 
PNFA = Progressive non fluent aphasia 77 
ORF = Open reading frame 78 
SD = Semantic Dementia 79 
TDP-43 pathology = TAR-DNA binding protein 43 pathology 80 
UTR = Untranslated region 81 
  82 
Introduction 83 
Frontotemporal dementia (FTD) is one of the leading causes of dementia in patients 84 
younger than 65 years of age[1, 2]. It is characterised by degeneration of the frontal and 85 
anterior temporal lobes leading to a decline in behaviour and language. FTD is a 86 
heterogeneous condition clinically, pathologically and genetically[2-4]. Clinically, it is 87 
broadly categorised into the behavioural variant (bvFTD) and the language variant or 88 
primary progressive aphasia (PPA), which is further categorised into semantic dementia 89 
(SD) and progressive non-fluent aphasia (PNFA). There is a frequent overlap between 90 
FTD and a number of motor diseases such as parkinsonian disorders, corticobasal 91 
syndrome, progressive supranuclear palsy and motor neuron disease (FTD-MND)[5]. 92 
The underlying pathological spectrum of FTD, termed frontal temporal lobar 93 
degeneration (FTLD), is based on neuronal lesions and protein inclusions such as with 94 
tau or TAR-DNA binding protein (TDP)-43 pathology. Beside the Mendelian genes 95 
MAPT, GRN and C9orf72 that are causal in up to ~30-50% of familial FTLD cases, rare 96 
variability in few other genes associates with less than 5% of cases[5-7]. To date only a 97 
couple of large genome wide association studies (GWAS) have been performed for 98 
FTD[8-10] reporting an association with TMEM106B for FTLD with TDP-43 99 
pathology[8], and with the locus comprising RAB38 and CTSC as well as the HLA-100 
DRA/HLA-DRB5 locus for bvFTD and FTD, respectively[9]. 101 
In a typical GWAS, an association test on a single variant (SNPs or Indels) is performed 102 
to map genes associated with a phenotype; however, many independent risk alleles for a 103 
given phenotype can be localised within a gene[11-13]. Hence a classical GWAS 104 
approach will be less powered to detect genes containing many independent risk 105 
alleles[14]. A joint-variant gene based test that combines independent association 106 
signals within a gene while accounting for the linkage disequilibrium (LD) between 107 
variants can overcome this limitation. A number of approaches have been reported to 108 
perform joint-SNP gene-based analysis: the permutation test – where empirical 109 
evidence of association of the combined test statistics is calculated by shuffling the 110 
samples while keeping markers intact – is currently considered the golden standard[15]. 111 
However, the requirement of genotype data and computational burden limits its use. 112 
Recently, our group developed a new approach called Multi-marker Analysis of 113 
GenoMic Annotation (MAGMA) that uses a multiple regression model to perform 114 
joint-SNP gene-based analysis using GWAS summary data[16]. 115 
In this study, we performed a hypothesis free gene-wide association study on FTD 116 
subtypes (bvFTD, SD, PNFA and FTD-MND) using GWAS summary files obtained 117 
from the International FTD-Genomics consortium (IFGC)[9]. We used the MAGMA 118 
software to perform the gene-based analysis. We report results of discovery, replication 119 
and combined cohort analyses for each FTD subtype; we also assessed individual risk 120 
variants for associated genes, which can be used for replication in the individual variant 121 
genotype setting. 122 
Methods 123 
Samples 124 
The dataset used in the FTD-GWAS was described previously[9]. Briefly, 44 125 
international groups contributed clinical FTD samples. Patients were diagnosed 126 
according to the Neary criteria or the revised criteria for bvFTD and language variants 127 
of FTD[17, 18]. Approximately 3% of cases were pathologically confirmed. For the 128 
current study we used the GWAS summary datasets of the discovery and replication 129 
cohorts of each FTD subtypes, bvFTD (discovery: 1377 cases and 2754 controls; 130 
replication: 690 cases and 5092 controls), PNFA (discovery: 269 cases and 538 131 
controls; replication: 221 cases and 5092 controls), SD (discovery: 308 cases and 616 132 
controls; replication: 189 cases and 5092 controls) and FTD-MND (discovery: 200 133 
cases and 400 controls; replication: 94 cases and 5092 controls). 134 
Statistical analysis 135 
We performed the joint-SNP gene-based analysis using MAGMA[16]. The MAGMA 136 
approach is based on a multiple linear principal components regression model. By 137 
projecting the multivariate LD matrix of SNPs in a gene it first extracts principal 138 
components that explain genetic variation. These principal components are further used 139 
as predictors of a phenotype under a linear regression framework. MAGMA then uses 140 
Fisher’s test to compute p-values to test association between a gene and the phenotype. 141 
We used 19418 hg19 annotated protein-coding genes to perform the analysis. Since all 142 
the samples involved were of European descent, we considered the 1000 genomes phase 143 
1 European reference population to estimate LD between variants[19]. We only 144 
considered SNPs in the 5’- and 3’-untranslated region (UTR) and the open reading 145 
frame (ORF) for the joint-SNP gene-based tests. This strategy resulted in loss of cis- 146 
regulatory variants, but was more stringent and ORF-specific. 147 
The schematic representation of the strategy for multi-stage gene-wide association 148 
analysis for FTD and subtypes is described in supplementary figure 1. We performed 149 
separate gene-based tests using discovery and replication datasets for each FTD subtype 150 
reported previously by the IFGC[9]. We performed gene-based tests using only those 151 
variants that were either genotyped or imputed with imputation score more than 0.50. 152 
Moreover we only considered common variants with minor allele frequency more than 153 
0.01. For individual FTD subtypes, 4303460 and 55375 variants were available for the 154 
gene-based analysis in the discovery and replication cohorts respectively. Further, 155 
16313 and 10349 genes that contained at least one variant within the 5’-, 3’-UTR and 156 
ORF, were tested for association with a given FTD subtype in the discovery and 157 
replication cohorts, respectively. To identify additional genes associated with individual 158 
FTD subtypes, we meta-analysed the gene-based p-values obtained in the discovery and 159 
replication cohorts using the Stouffer’s combination approach for the sample size 160 
weighted combination of p-values. For each FTD subtype we tested association of total 161 
16920 genes either in the discovery or replication cohorts. To correct for multiple 162 
association tests performed for 16920 genes with one of the four subtypes of FTD, we 163 
applied the conservative Bonferroni correction method establishing a gene-wide 164 
significance threshold at 7.388 × 10-07 (= 0.05 / (4 ×	16920)). To identify genes 165 
associated with any FTD subtype, we combined the gene-based test statistics for either 166 
subtype (bvFTD, SD, PNFA and FTD-MND) using the sample size weighted Stouffer’s 167 
combination method. 168 
Functional characterisation of associated genes 169 
We downloaded the gene expression profiles of the associated genes across 13 human 170 
brain tissues (in alphabetically order: amygdala, anterior cingulate cortex, caudate, 171 
cerebral hemisphere, cerebellum, cortex, frontal cortex, hippocampus, nucleus 172 
accumbens, putamen, spinal cord, substantia nigra) using the GTEx portal[20] (GTEx 173 
Analysis V6 dbGaP Accession phs000424.v6.p1). We also investigated the functional 174 
annotations of variants that are in LD (r2 > 0.8 in the 1000 genomes phase 1 European 175 
panel) with SNPs used in deriving gene-based p-values of the associated genes using 176 
software HaploReg[21] (version 4.1) and RegulomeDB[22] (version 1.1). 177 
Results 178 
Associations with FTD and its subtypes 179 
bvFTD 180 
In the discovery cohort, two genes passed the gene-wide significant p-value threshold 181 
7.388 × 10-07: TOMM40 (p = 5.786 × 10-8) and APOE (p = 1.367 × 10-7). In the 182 
replication cohort the p-values were 6.40 × 10-5 for TOMM40 and 1.688 × 10-3 for 183 
APOE suggesting consistency of associations across independent bvFTD samples. No 184 
other genes passed the significance threshold for the bvFTD subtype (supplementary 185 
figure 2a). 186 
Interestingly, in the discovery cohort the SNPs rs7412 and rs429358, which determine 187 
three epsilon (ε) alleles ε2, ε3 and ε4 of the APOE gene, were among the SNPs driving 188 
its association with bvFTD, with p-values 0.023 (rs7412) and 5.04 × 10-6 (rs429358). In 189 
the replication cohort rs429358 was not genotyped, whereas information on rs769449, 190 
an intronic variant in high LD (r2 = 0.82, 1000 Genomes phase 1 European population) 191 
with rs429358, was available; here the p-values were 0.222 for rs7412 and 1.945 × 10-4 192 
for rs769449. 193 
To check whether the association of TOMM40 with bvFTD was independent of the 194 
epsilon variants, we re-performed the gene-based test on TOMM40 gene using only 195 
those variants in negligible LD (r2 < 0.2) with rs7412 and rs429358 in 1000 genomes 196 
phase 1 European panel. This analysis showed moderate association of TOMM40 with 197 
bvFTD (p = 7.513 × 10-6; table 1) suggesting that the TOMM40 gene harbours signals 198 
for the risk of bvFTD that are independent of the epsilon alleles of APOE gene. 199 
The summary statistics of variants used for deriving gene-based p-values for TOMM40 200 
and APOE are given in supplementary tables 2a and 2b respectively, and the regional 201 
plots are shown in figure 1a and 1b. The regional plots show many variants in TOMM40 202 
with p-values less than 0.05 that are in negligible LD (r2 < 0.2) with rs769449, a proxy 203 
of epsilon variant rs429358. 204 
 205 
FIGURE 1A and 1B Regional plots at the TOMM40/APOE locus in bvFTD cohorts 206 
 207 
PNFA 208 
The joint-cohort (discovery and replication) analysis revealed association for 209 
ARHGAP35 (p = 2.950 × 10-7) and SERPINA1 (p = 3.024 × 10-7) with PNFA (table 1 210 
and supplementary table 3). The regional plots for ARHGAP35 and SERPINA1  (figure 211 
2a and 2b respectively) show a robust LD block only for ARHGAP35 for which all 212 
variants show association p-values less than 0.05 with PNFA (also refer to 213 
supplementary table 3a). In SERPINA1 many LD independent variants with PNFA 214 
association p-values less than 0.05 can be observed. 215 
 216 
FIGURE 2 Regional plots at A) ARHGAP35 and B) SERPINA1 loci in PNFA 217 
cohorts 218 
 219 
SD 220 
No gene exceeded the gene-wide significance threshold 7.388 × 10-07, possibly because 221 
of smaller sample size, thus reduced power. The top gene identified in the combined 222 
analysis was WDR66 (p = 9.50 × 10-6; supplementary table 1). 223 
FTD-MND 224 
No gene reached gene-wide significant association in the FTD-MND subtype. However, 225 
the top genes for FTD-MND were C9orf72 and IFNK with gene-based association p-226 
value in joint-cohort analysis 1.232 × 10-6 and 1.77 x 10-6, respectively. Neither gene 227 
showed associations with any other subtypes of FTD (refer to supplementary table 1). 228 
FTD meta-analysis 229 
The meta-analysis across all subtypes (bvFTD, SD, PNFA and FTD-MND) identified 230 
association of TOMM40 and APOE. It is worth noting that the bvFTD samples make 231 
more than 1/3rd of the total sample; hence, p-values for association with bvFTD 232 
dominated the meta-analysis of FTD subtypes. 233 
  234 
TABLE 1: Significantly associated genes (p < 7.388 × 10-07) with FTD and its 235 
subtypes. Gene-wide significant p-values (p < 7.388 × 10-07) are highlighted in bold. 236 
Phenotype Symbol Chr Start Stop Stage1 
nSNPs 
Stage1 
P 
Stage2 
nSNPs 
Stage2 p Combined p 
bvFTD TOMM40 19 45394477 45406946 29 5.786 × 10-8 13 6.40 × 10-5 5.43 × 10-11 
APOE 19 45409039  45412650 5 1.367 × 10-7 2 1.688 × 10-3 1.688 × 10-9 
TOMM40 
after removing 
variants in LD 
(r2 >= 0.2) 
with the 
epsilon 
variants 
19 45394477 45406946 18 1.949 × 10-5 5 0.073 7.513 × 10-6 
PNFA ARHGAP35 19 47421933 47508334 25 4.262 × 10-6 12 7.157 × 10-3  2.950 × 10-7 
SERPINA1 14 94843084  94857029 50 3.712 × 10-5 8 1.193 × 10-3 3.024 × 10-7 
All FTD TOMM40 19 45394477 45406946 NA NA NA NA 4.982 × 10-11 
APOE 19 45409039  45412650 NA NA NA NA 2.179 × 10-10 
 237 
  238 
Risk of APOE alleles on FTD subtypes 239 
Based on the gene-based association results with TOMM40 and APOE we extended our 240 
analysis to the epsilon alleles and genotypes. We compared each FTD case cohort 241 
(discovery, replication and combined) against a total of 9390 ancestry matched controls 242 
using Fisher’s exact test. For replication cohorts, we used rs769449 as a proxy for 243 
rs429358. The distribution of epsilon alleles and genotypes in our cohort is given in 244 
supplementary table 4 and 5, respectively. We established the significance threshold for 245 
allele associations as 4.167 × 10-3 (0.05/12) correcting for three epsilon alleles and four 246 
FTD subtypes. We identified the ε2 allele significantly reduces the risk of bvFTD (odds 247 
ratio = 0.772, p = 3.878 × 10-4) and SD (odds ratio = 0.651, p = 3.642 × 10-3). We 248 
observed marginal association (p < 0.05) of ε2 allele with PNFA (odds ratio = 0.706, p 249 
= 0.019) and moderate with FTD-MND (odds ratio = 0.571, p = 6.008 × 10-3). The ε4 250 
allele significantly increased risk of bvFTD (odds ratio = 1.278, p = 8.14 × 10-6) and SD 251 
(odds ratio = 1.438, p = 2.931 × 10-4). The association for disease increasing effect of ε4 252 
allele was marginal (p < 0.05) for PNFA (odds ratio = 1.29, p = 0.011), but the result 253 
was inconclusive for FTD-MND (odds ratio = 1.19, p = 0.20) possibly due to 254 
underpowered sample size. 255 
We also quantified the risk of homozygous ε4/ε4 genotype on FTD subtypes. We used 256 
1.25 × 10-2 as a significance threshold for association testing of four subtypes with 257 
homozygous ε4/ε4 genotype. The homozygous ε4/ε4 genotype showed significant 258 
association with increased risk for bvFTD (odds ratio = 1.62, p = 0.012), PNFA (odds 259 
ratio = 2.36, p = 8.52 × 10-3) and SD (odds ratio = 2.33, p = 9.08 × 10-3) with notable 260 
odds ratio values for PNFA and SD compared to the effect size of a single copy of ε4 261 
allele for respective FTD subtypes. We did not perform association between 262 
homozygous ε2/ε2 genotypes with FTD subtypes due to its low frequency in our cohort. 263 
  264 
Table 2: The odds of clinical subtypes of FTD and epsilon alleles, and homozygous 265 
ε4/ε4 genotype. 266 
 ε2 allele ε3 allele ε4 allele ε4/ε4 genotype 
Case 
cohort 
Odd
s 
ratio 
Conf. 
interval p-value 
Odds 
ratio 
Conf. 
interval p-value 
Odds 
ratio 
Conf. 
interval p-value 
Odds 
ratio 
Conf. 
interva
l p-value 
bvFTD 
discovery 
0.83
4 
 0.696-
0.994 0.041 0.908 
0.817-
1.011 0.076 1.341 
1.182-
1.517 
5.00 × 
10-6 1.737 
1.090-
2.682 0.018 
bvFTD 
replication 
0.77
1 
0.598-
0.980 0.0311 0.943 
0.815-
1.094 0.431 1.154 
0.961-
1.38 0.11 1.407 
0.679-
2.637 0.27 
bvFTD 
combined 
0.77
2 
0.664-
0.894 
3.878 × 
10-4 0.92 
0.841-
1.006 0.066 1.278 
1.147-
1.421 
8.14 × 
10-6 1.627 
1.089-
2.384 0.0123 
             
PNFA 
discovery 
0.79
2 
0.526-
1.150 0.261 0.95 
0.755-
1.205 0.639 1.246 
0.938-
1.631 0.12 2.320 
0.902-
5.015 0.04 
PNFA 
replication 
0.60
2 
0.358-
0.956 0.028 0.971 
0.754-
1.266 0.796 1.363 
1.006-
1.816 0.041 2.423 
0.860 
5.537 0.046 
PNFA 
combined 
0.70
6 
0.515-
0.947 0.0193 0.96 
0.808-
1.145 0.628 1.298 
1.056-
1.584 0.011 2.367 
1.211-
4.261 
8.518 × 
10-3 
             
SD 
discovery 
0.80
8 
0.554-
1.143 0.258 0.764 
0.625-
0.940 0.01 1.649 
1.3-
2.073 
4.33 × 
10-5 2.614 
1.152-
5.218 0.011 
SD 
replication 
0.40
2 
0.198-
0.730 
9.473 × 
10-4 1.217 
0.906-
1.664 0.208 1.112 
0.777-
1.552 0.537 1.878 
0.497-
5.031 0.176 
SD 
combined 
0.65
1 
0.470-
0.880 
3.642 × 
10-3 0.898 
0.759-
1.066 0.205 1.438 
1.181-
1.741 
2.931 × 
10-4 2.333 
1.194-
4.199 
9.076 × 
10-3 
             
FTD-MND 
discovery 
0.52
2 
0.289-
0.876 
9.299 × 
10-3 1.042 
0.793-
1.388 0.838 1.311 
0.948-
1.78 0.087 
1.323
55 
0.266-
4.028 0.500 
FTD-MND 
replication 
0.67
4 
0.303-
1.313 0.311 1.134 
0.754-
1.764 0.622 0.934 
0.53-
1.544 0.901 0 
0.000-
3.536 0.629 
FTD-MND 
combined 
0.57
1 
0.361-
0.862 
6.008 × 
10-3 1.070 
0.852-
1.357 0.612 1.188 
0.901-
1.544 0.202 0.895 
0.181-
2.714 1 
  267 
Functional characterisation of associated genes 268 
We extracted the gene expression profiles of APOE, TOMM40, ARHGAP35 and 269 
SERPINA1 across different human brain tissues from the GTeX database[20]; see 270 
supplementary figure 3 (a, b, c and d for respective genes). The APOE, TOMM40 and 271 
ARHGAP35 genes are strongly expressed in different brain tissues. Notably the anterior 272 
cingulate cortex (Bordmann area 24) and the frontal cortex (Bordmann area 9) are the 273 
top tissues for ARHGAP35 gene expression. The Anterior cingulate cortex is one of the 274 
early affected regions in FTD patients[23, 24]; this area is reported to be involved in 275 
language control and resolving nonverbal conflict[25]. The SERPINA1 gene did not 276 
show strong expression in the brain tissues. 277 
We used the HaploReg[21] (version 4.1) software to investigate functionally annotated 278 
variants linked with variants used in deriving gene-based p-values of TOMM40 (those 279 
in negligible LD r2 < 0.2 with epsilon variants), ARHGAP35, and SERPINA1 280 
respectively. We found that all SNPs used in deriving gene-based p-values of TOMM40, 281 
ARHGAP35 and SERPINA1 are in strong LD (r2 > 0.8, in 1000 genomes phase 1 282 
European panel) with at least one variant residing in the regulatory regions such as 283 
chromatin marks or DNase hypersensitive sites, suggesting a possible regulatory roles 284 
(see supplementary figures 6a, 6b and 6c for HaploReg results for variants in TOMM40, 285 
ARHGAP35 and SERPINA1 respectively). Overall we identified 21, 56 and 93 286 
regulatory variants in LD with SNPs deriving gene-based p-values of TOMM40, 287 
ARHGAP35, and SERPINA1 genes respectively. We further ranked these regulatory 288 
variants based on their functional relevance using the RegulomeDB[22] (version 1.1) 289 
software (see supplementary tables 7a, 7b and 7c for detailed RegulomeDB results of 290 
these variants mapped to TOMM40, ARHGAP35 and SERPINA1 genes respectively). 291 
Discussion 292 
Here we report novel genetic insight into FTD and its clinical subtypes using a joint-293 
SNP gene-based approach. We identified association of the TOMM40 and APOE genes 294 
with bvFTD, and the ARHGAP35 and SERPINA1 genes with PNFA. 295 
Our study suggested TOMM40 as the top gene in bvFTD. The TOMM40 gene encodes a 296 
channel forming subunit of the translocase of the mitochondrial outer membrane (TOM 297 
complex), which facilitates translocation of unfolded proteins from the cytosol into the 298 
mitochondrial intermembrane space for use in oxidative phosphorylation[26]. Recently 299 
Bannwarth et al.[27] reported mitochondrial origin in pathogenesis of FTD-ALS 300 
diseases through association of variants in CHCHD10. There is growing evidence 301 
suggesting a role of mitochondria in neurodegenerative disorders, also including 302 
Parkinson’s[28, 29], Huntington’s[30] and Alzheimer’s disease[31, 32]. 303 
The association of the APOE gene with bvFTD was primarily driven by SNPs rs7412 304 
and rs429358 (or variants in strong LD such as rs769449). The SNPs rs7412 and 305 
rs429358 determine the APOE epsilon alleles ε2, ε3 and ε4. We quantified the risk of 306 
epsilon alleles across clinical subtypes of FTD diagnosed using the Neary’s criteria and 307 
saw that the ε2 and ε4 alleles showed protective and increased disease risk effects, 308 
respectively, for FTD subtypes (strong associations for bvFTD and SD, and marginal 309 
associations for PNFA and FTD-MND). Interestingly, individuals carrying homozygous 310 
copies of the ε4 allele revealed higher risk for PNFA and SD (odds ratio > 2.3), 311 
suggesting dose dependent effect for each copy of a gene. The pattern of association of 312 
epsilon alleles with FTD subtypes might reflect on the potential overlap between 313 
patients diagnosed with clinical FTD and Alzheimer’s disease[33, 34] or a genuine 314 
association with FTD and its subtypes given the increasing number of studies arguing in 315 
favour of the latter hypothesis[10, 35-38]. 316 
In the central nervous system (CNS) APOE is synthesised in response to neuronal injury 317 
or stress to initiate the neuronal repair mechanisms. The ε4 carriers are hypothesised to 318 
have reduced neuronal repair capacity compared to the other alleles[37]. The protein 319 
products of APOE were also reported to modulate neuroinflammation[39]. The 320 
hypothesis of enhanced inflammatory response in FTD patients is supported by both 321 
neuroimaging and genetic studies[40, 41]. Tau pathology is found in up to ~50% of 322 
FTLD cases[42]; interestingly the knock-in study in mice showed association between 323 
epsilon alleles and the concentration of hyper-phosphorylated tau in neurons: ε4 knock 324 
in mice showed higher concentration of hyper-phosphorylated tau than ε3 knock in 325 
mice[43]. It is worth noting that in this scenario the APOE locus and the epsilon allelic 326 
variability might impact processes such as modulation of neuronal repair mechanisms, 327 
neuroinflammation, broad lipid metabolism, synaptic plasticity, neuronal toxicity and 328 
tau phosphorylation[44]. It is likely that variability in the genes or isoforms turnover or 329 
larger haplotype blocks at this locus, coupled with aging, might influence negative 330 
outcomes in brain and thus support our findings from a biological and functional 331 
perspective. More work should be directed towards testing these possibilities in the 332 
future. 333 
Our study is the first to report association of the ARHGAP35 and SERPINA1 genes with 334 
PNFA. The ARHGAP35 gene encodes the glucocorticoid receptor DNA-binding factor 335 
1, which is a repressor of glucocorticoid receptor (hGR) transcription. At the cellular 336 
level, the glucocorticoid receptor mediates the maintenance of basal and stress-related 337 
homeostasis. The second gene we found associated with PNFA was SERPINA1, which 338 
was previously reported to be associated with cortisol level[45] (top variants: 339 
rs11621961, rs12589136, rs2749527) and serum lipid profile[46] (top variant: rs1303). 340 
The nonsynonymous variant rs1303 (Glu400Asp) in SERPINA1, which is also in 341 
moderate LD with morning plasma cortisol level associated variant rs12589136[45], 342 
showed PNFA association p-values less than 0.05 in both discovery and replication 343 
cohorts (supplementary table 3a). The top SERPINA1 variant in the PNFA discovery 344 
cohort rs11628917 (this variant in moderate LD with rs1303) is an established blood 345 
eQTL[47], with the C allele increasing SERPINA1 expression in blood[46, 47]. We 346 
observed that the C allele at rs11628917 increased the risk of PNFA in both discovery 347 
and replication cohorts. The SERPINA1 gene encodes protease inhibitor α1-antitrypsin 348 
enzyme, which inhibits cleavage of the reactive centre loop of the corticosteroid binding 349 
globulin (CBG) by ceasing neutrophil elastase activity[48]. The reactive centre loop 350 
cleavage by neutrophil elastase reduces the CBG binding affinity to cortisol. During 351 
stress CBG activity is positively correlated with the glucocorticoid access to the 352 
brain[49]. Increased glucocorticoid level in brain can activate glucocorticoid signalling 353 
through binding to the low affinity glucocorticoid receptors and result in the reduced 354 
neurogenesis and impaired neuroplasticity[50]. This hypothesis suggesting the role of 355 
enhanced glucocorticoid signalling leading to neurodegeneration in PNFA patients is 356 
based on our current preliminary report on association of ARHGAP35 and SERPINA1 357 
with PNFA; this finding will need to be further explored and replicated in an 358 
independent cohort. 359 
In conclusion, we report novel genetic associations for frontotemporal dementia and its 360 
subtypes – notably of the TOMM40 and APOE genes with bvFTD and the ARHGAP35 361 
and SERPINA1 genes with PNFA – using the joint-SNP gene-based approach. This 362 
approach improves power of the association test by combining signals across variants in 363 
a functional unit such as a gene. Replication and functional characterisation of these 364 
findings will further establish their role in pathology of the frontotemporal dementia and 365 
help towards a better management of the disease. 366 
  367 
Acknowledgements 368 
The Netherlands Organization for Scientific Research (NWO VICI 453-14-005) funded 369 
this work. RF is supported by the Alzheimer’s Society (grant number 284). 370 
We acknowledge the investigators of the original GWAS by IFGC, the 371 
acknowledgments as well as the consortia members are listed within the supplementary 372 
text (Appendix A and B). 373 
We also acknowledge contributors to the Genotype-Tissue Expression (GTEx) Project, 374 
described in the supplementary text (Appendix C). 375 
 376 
  377 
References 378 
[1] Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, 379 
pathophysiology, diagnosis and management. CNS Drugs. 2010;24:375-98. 380 
[2] Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic 381 
and pathological heterogeneity of frontotemporal dementia: a review. J Neurol 382 
Neurosurg Psychiatry. 2011;82:476-86. 383 
[3] Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. 384 
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar 385 
degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. 386 
Acta Neuropathol. 2007;114:5-22. 387 
[4] Mackenzie IR, Rademakers R. The molecular genetics and neuropathology of 388 
frontotemporal lobar degeneration: recent developments. Neurogenetics. 2007;8:237-48. 389 
[5] Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, et al. The 390 
heritability and genetics of frontotemporal lobar degeneration. Neurology. 391 
2009;73:1451-6. 392 
[6] Ferrari R, Thumma A, Momeni P. Molecular Genetics of Frontotemporal Dementia.  393 
eLS: John Wiley & Sons, Ltd; 2001. 394 
[7] Woollacott IO, Rohrer JD. The clinical spectrum of sporadic and familial forms of 395 
frontotemporal dementia. J Neurochem. 2016. 396 
[8] Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-397 
Radford NR, et al. Common variants at 7p21 are associated with frontotemporal lobar 398 
degeneration with TDP-43 inclusions. Nat Genet. 2010;42:234-9. 399 
[9] Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, et al. 400 
Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet 401 
Neurol. 2014;13:686-99. 402 
[10] Ferrari R, Grassi M, Salvi E, Borroni B, Palluzzi F, Pepe D, et al. A genome-wide 403 
screening and SNPs-to-genes approach to identify novel genetic risk factors associated 404 
with frontotemporal dementia. Neurobiol Aging. 2015;36:2904 e13-26. 405 
[11] Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ATC, 406 
Replication DIG, et al. Conditional and joint multiple-SNP analysis of GWAS summary 407 
statistics identifies additional variants influencing complex traits. Nat Genet. 408 
2012;44:369-75, S1-3. 409 
[12] Zhang J, Zhang Y, Yang J, Zhang L, Sun L, Pan HF, et al. Three SNPs in 410 
chromosome 11q23.3 are independently associated with systemic lupus erythematosus 411 
in Asians. Hum Mol Genet. 2014;23:524-33. 412 
[13] Tada H, Won HH, Melander O, Yang J, Peloso GM, Kathiresan S. Multiple 413 
associated variants increase the heritability explained for plasma lipids and coronary 414 
artery disease. Circ Cardiovasc Genet. 2014;7:583-7. 415 
[14] Hagg S, Ganna A, Van Der Laan SW, Esko T, Pers TH, Locke AE, et al. Gene-416 
based meta-analysis of genome-wide association studies implicates new loci involved in 417 
obesity. Hum Mol Genet. 2015;24:6849-60. 418 
[15] Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, et al. A 419 
versatile gene-based test for genome-wide association studies. Am J Hum Genet. 420 
2010;87:139-45. 421 
[16] de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set 422 
analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219. 423 
[17] Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. 424 
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. 425 
Neurology. 1998;51:1546-54. 426 
[18] Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. 427 
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal 428 
dementia. Brain. 2011;134:2456-77. 429 
[19] Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin 430 
RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 431 
2012;491:56-65. 432 
[20] Mele M, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth M, et al. 433 
Human genomics. The human transcriptome across tissues and individuals. Science. 434 
2015;348:660-5. 435 
[21] Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, 436 
conservation, and regulatory motif alterations within sets of genetically linked variants. 437 
Nucleic Acids Res. 2012;40:D930-4. 438 
[22] Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. 439 
Annotation of functional variation in personal genomes using RegulomeDB. Genome 440 
Res. 2012;22:1790-7. 441 
[23] Seeley WW, Carlin DA, Allman JM, Macedo MN, Bush C, Miller BL, et al. Early 442 
frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol. 443 
2006;60:660-7. 444 
[24] Seeley WW, Crawford R, Rascovsky K, Kramer JH, Weiner M, Miller BL, et al. 445 
Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal 446 
dementia. Arch Neurol. 2008;65:249-55. 447 
[25] Abutalebi J, Della Rosa PA, Green DW, Hernandez M, Scifo P, Keim R, et al. 448 
Bilingualism tunes the anterior cingulate cortex for conflict monitoring. Cereb Cortex. 449 
2012;22:2076-86. 450 
[26] Mager F, Gessmann D, Nussberger S, Zeth K. Functional refolding and 451 
characterization of two Tom40 isoforms from human mitochondria. J Membr Biol. 452 
2011;242:11-21. 453 
[27] Bannwarth S, Ait-El-Mkadem S, Chaussenot A, Genin EC, Lacas-Gervais S, 454 
Fragaki K, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic 455 
lateral sclerosis through CHCHD10 involvement. Brain. 2014;137:2329-45. 456 
[28] Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. 457 
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990;54:823-458 
7. 459 
[29] Parker WD, Jr., Boyson SJ, Parks JK. Abnormalities of the electron transport chain 460 
in idiopathic Parkinson's disease. Ann Neurol. 1989;26:719-23. 461 
[30] Moran M, Moreno-Lastres D, Marin-Buera L, Arenas J, Martin MA, Ugalde C. 462 
Mitochondrial respiratory chain dysfunction: implications in neurodegeneration. Free 463 
Radic Biol Med. 2012;53:595-609. 464 
[31] Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M. Mitochondria and 465 
neurodegeneration. Biosci Rep. 2007;27:87-104. 466 
[32] Hroudova J, Singh N, Fisar Z. Mitochondrial dysfunctions in neurodegenerative 467 
diseases: relevance to Alzheimer's disease. Biomed Res Int. 2014;2014:175062. 468 
[33] Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672-82. 469 
[34] van der Zee J, Sleegers K, Van Broeckhoven C. Invited article: the Alzheimer 470 
disease-frontotemporal lobar degeneration spectrum. Neurology. 2008;71:1191-7. 471 
[35] Engelborghs S, Dermaut B, Marien P, Symons A, Vloeberghs E, Maertens K, et al. 472 
Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe 473 
dementia. Neurobiol Aging. 2006;27:285-92. 474 
[36] Agosta F, Vossel KA, Miller BL, Migliaccio R, Bonasera SJ, Filippi M, et al. 475 
Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in 476 
Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A. 477 
2009;106:2018-22. 478 
[37] Rubino E, Vacca A, Govone F, De Martino P, Pinessi L, Rainero I. Apolipoprotein 479 
E polymorphisms in frontotemporal lobar degeneration: a meta-analysis. Alzheimers 480 
Dement. 2013;9:706-13. 481 
[38] Seripa D, Bizzarro A, Panza F, Acciarri A, Pellegrini F, Pilotto A, et al. The APOE 482 
gene locus in frontotemporal dementia and primary progressive aphasia. Arch Neurol. 483 
2011;68:622-8. 484 
[39] Tai LM, Ghura S, Koster KP, Liakaite V, Maienschein-Cline M, Kanabar P, et al. 485 
APOE-modulated Abeta-induced neuroinflammation in Alzheimer's disease: current 486 
landscape, novel data, and future perspective. J Neurochem. 2015;133:465-88. 487 
[40] Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB. In vivo detection of 488 
microglial activation in frontotemporal dementia. Ann Neurol. 2004;56:894-7. 489 
[41] Rainero I, Rubino E, Cappa G, Rota E, Valfre W, Ferrero P, et al. Pro-490 
inflammatory cytokine genes influence the clinical features of frontotemporal lobar 491 
degeneration. Dement Geriatr Cogn Disord. 2009;27:543-7. 492 
[42] Halliday G, Bigio EH, Cairns NJ, Neumann M, Mackenzie IR, Mann DM. 493 
Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus 494 
loss of function effects. Acta Neuropathol. 2012;124:373-82. 495 
[43] Inbar D, Belinson H, Rosenman H, Michaelson DM. Possible role of tau in 496 
mediating pathological effects of apoE4 in vivo prior to and following activation of the 497 
amyloid cascade. Neurodegener Dis. 2010;7:16-23. 498 
[44] Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's 499 
disease and other neurological disorders. Lancet Neurol. 2011;10:241-52. 500 
[45] Bolton JL, Hayward C, Direk N, Lewis JG, Hammond GL, Hill LA, et al. Genome 501 
wide association identifies common variants at the SERPINA6/SERPINA1 locus 502 
influencing plasma cortisol and corticosteroid binding globulin. PLoS Genet. 503 
2014;10:e1004474. 504 
[46] Inouye M, Ripatti S, Kettunen J, Lyytikainen LP, Oksala N, Laurila PP, et al. 505 
Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for 506 
atherosclerosis. PLoS Genet. 2012;8:e1002907. 507 
[47] Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. 508 
Systematic identification of trans eQTLs as putative drivers of known disease 509 
associations. Nat Genet. 2013;45:1238-43. 510 
[48] Lewis JG, Elder PA. The reactive centre loop of corticosteroid-binding globulin 511 
(CBG) is a protease target for cortisol release. Mol Cell Endocrinol. 2014;384:96-101. 512 
[49] Moisan MP, Minni AM, Dominguez G, Helbling JC, Foury A, Henkous N, et al. 513 
Role of corticosteroid binding globulin in the fast actions of glucocorticoids on the 514 
brain. Steroids. 2014;81:109-15. 515 
[50] Anacker C, Zunszain PA, Carvalho LA, Pariante CM. The glucocorticoid receptor: 516 
pivot of depression and of antidepressant treatment? Psychoneuroendocrinology. 517 
2011;36:415-25. 518 
 519 
